Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Travoprost Cream in Open-angle Glaucoma or Ocular Hypertension
NCT06152861Phase 2Recruiting
- Sponsor
- Glaukos Corporation
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (5 arms), sponsored by Glaukos Corporation. Primary endpoint: Change from baseline in mean diurnal Intraocular Pressure in the study eye at Day 29. Started Nov 2023; status: recruiting.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT06152861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06152861.